The study is designed to assess the frequency and severity of few dose limiting neurological adverse effects of four different schedules of FOLFOX. Patients with histologically confirmed advanced colorectal carcinoma (CRC) were included in the study. Toxicity was graded according to CTC v 2.0. The frequency of grade 3 and 4 adverse effects was comparatively assessed in each treatment arm. The difference in the pattern of toxicity between the treatment schedule was evaluated. The most frequent adverse symptom of neurological adverse effect was grade 1 paresthesia in the patients treated with FOLFOX4 schedule. Grade 4 peripheral neuropathy was reported in few patients of FOLFOX7 treatment arm. Frequency and onset of neurological adverse effects like paresthesia, dizziness, and hypoesthesia were significantly different ( ), whereas frequency and onset of peripheral neuropathy were highly significant ( ) in each treatment arm of FOLFOX. Peripheral neuropathy was associated with electrolyte imbalance and diabetes in few patients. Frequency of symptoms, for example, paresthesia, is associated with increased number of recurrent exposure to oxaliplatin (increased number of cycles) even at low doses (85？mg/m2), whereas severity of symptoms, for example, peripheral neuropathy, is associated with higher dose (130？mg/m2) after few treatment cycles. 1. Introduction Incorporation of Oxaliplatin in 5FU/LV regimen has increased the median overall survival rate and progression free survival in patients of advanced colorectal carcinoma. The most frequent dose limiting toxicity of Oxaliplatin is peripheral neuropathy next to neutropenia. Neurotoxicity of Oxaliplatin is exacerbated as an acute sensory transient response, for example, paresthesia and dysesthesia in hand, feet, and peri oral area [1], which appears during or after exposure to Oxaliplatin. Sensory neurotoxicity with oxaliplatin is progressive, cumulative, and reversible, often manifested as delayed effects (12 to 18 months after discontinuation of the therapy). Peripheral neuropathy is hence regarded as the main “safety concern” for chemotherapy with Oxaliplatin, evident as frequent distal, transient paresthesia within the first few minutes of infusion [2]. The cumulative peripheral sensory neuropathy at the total dose of 800？mg/m2 requires cessation of therapy [3]. Acute syndrome of neurotoxicity is evident in 1-2% of patients shortly after the infusion, whereas the chronic syndrome is manifested as a dose limiting toxicity in 12–15% patients at the cumulative dose of 780–850？mg/m2 [4]. The platinum
References
[1]
E. Raymond, R. Lawrence, E. Izbicka, S. Faivre, and D. D. Von Hoff, “Activity of oxaliplatin against human tumor colony-forming units,” Clinical Cancer Research, vol. 4, no. 4, pp. 1021–1029, 1998.
[2]
T. André, C. Boni, L. Mounedji-Boudiaf et al., “Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2343–2351, 2004.
[3]
D. Simpson, C. Dunn, M. Curran, and K. L. Goa, “Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer,” Drugs, vol. 63, no. 19, pp. 2127–2156, 2003.
[4]
M. W. Saif and J. Reardon, “Management of oxaliplatin-induced peripheral neuropathy,” Therapeutic and Clinical Risk Management, vol. 1, no. 4, pp. 249–258, 2005.
[5]
E. S. McDonald, K. R. Randon, A. Knight, and A. J. Windebank, “Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity,” Neurobiology of Disease, vol. 18, no. 2, pp. 305–313, 2005.
[6]
A. A. Argyriou, P. Polychronopoulos, G. Iconomou et al., “Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer,” Acta Oncologica, vol. 46, no. 8, pp. 1131–1137, 2007.
[7]
G. Cavaletti, G. Tredici, M. G. Petruccioli et al., “Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat,” European Journal of Cancer, vol. 37, no. 18, pp. 2457–2463, 2001.
[8]
A. Binder, M. Stengel, R. Maag et al., “Pain in oxaliplatin-induced neuropathy—sensitisation in the peripheral and central nociceptive system,” European Journal of Cancer, vol. 43, no. 18, pp. 2658–2663, 2007.
[9]
S. B. Park, C. S.-Y. Lin, A. V. Krishnan, D. Goldstein, M. L. Friedlander, and M. C. Kiernan, “Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy,” Brain, vol. 132, no. 10, pp. 2712–2723, 2009.
[10]
M. C. Kiernan, S. B. Park, D. Goldstein, C. S.-Y. Lin, A. V. Krishnan, and M. L. Friedlander, “Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1243–1249, 2009.
[11]
C. L. Renn, V. A. Carozzi, P. Rhee, D. Gallop, S. G. Dorsey, and G. Cavaletti, “Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice,” Molecular Pain, vol. 7, article 29, 2011.
[12]
S. M. F. Jamieson, J. Subramaniam, J. J. Liu et al., “Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue,” Molecular Pain, vol. 5, article 66, 2009.
[13]
T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot, “Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy,” Clinical Cancer Research, vol. 12, no. 10, pp. 3050–3056, 2006.
[14]
L. Gamelin, O. Capitain, A. Morel et al., “Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway,” Clinical Cancer Research, vol. 13, no. 21, pp. 6359–6368, 2007.
[15]
M. C. Kiernan and A. V. Krishnan, “The pathophysiology of oxaliplatin-induced neurotoxicity,” Current Medicinal Chemistry, vol. 13, no. 24, pp. 2901–2907, 2006.
[16]
F. Wen, Y. Zhou, W. Wang et al., “Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis,” Annals of Oncology, vol. 24, no. 1, pp. 171–178, 2013.
[17]
X. T. Xu, Z. H. Dai, Q. Xu, et al., “Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers,” Journal of Digestive Diseases, vol. 14, no. 6, pp. 288–298, 2013.
[18]
A. Grothey, Q. Rui, D. Shaker, et al., “o-0032 phase III randomized, placebo (pl)-controlled, double-blind study of intravenous calcium/magnesium (camg) to prevent oxaliplatin-induced sensory neurotoxicity (snt), n08cb: an alliance for clinical trials in oncology study1,” Annals of Oncology, vol. 24, supplement 4, Article ID iv24, 2013.
[19]
Gobran and S. Nagy, “Role of calcium and magnesium infusion in prevention of oxaliplatin neurotoxicity. A phase III trial,” The Chinese-German Journal of Clinical Oncology, vol. 12, no. 5, pp. 232–236, 2013.
[20]
de Afonseca, O. Samuel, M. C. Felipe, et al., “Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial,” Sao Paulo Medical Journal, vol. 131, no. 1, pp. 35–38, 2013.
[21]
A. Grothey, D. A. Nikcevich, J. A. Sloan et al., “Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7,” Journal of Clinical Oncology, vol. 29, no. 4, pp. 421–427, 2011.
[22]
N. Knijn, J. Tol, M. Koopman et al., “The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients,” European Journal of Cancer, vol. 47, no. 3, pp. 369–374, 2011.
[23]
L. A. Kottschade, J. A. Sloan, M. A. Mazurczak et al., “The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial,” Supportive Care in Cancer, vol. 19, no. 11, pp. 1769–1777, 2011.
[24]
K. Ishibashi, N. Okada, T. Miyazaki, M. Sano, and H. Ishida, “Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study,” International Journal of Clinical Oncology, vol. 15, no. 1, pp. 82–87, 2010.
[25]
W.-Y. Chay, S.-H. Tan, Y.-L. Lo et al., “Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy,” Asia-Pacific Journal of Clinical Oncology, vol. 6, no. 4, pp. 270–277, 2010.
[26]
L. Gamelin, M. Boisdron-Celle, R. Delva et al., “Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer,” Clinical Cancer Research, vol. 10, no. 12, pp. 4055–4061, 2004.
[27]
S. Wolf, D. Barton, L. Kottschade, A. Grothey, and C. Loprinzi, “Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies,” European Journal of Cancer, vol. 44, no. 11, pp. 1507–1515, 2008.
[28]
A. J. Windebank and W. Grisold, “Chemotherapy-induced neuropathy,” Journal of the Peripheral Nervous System, vol. 13, no. 1, pp. 27–46, 2008.
[29]
J. Graham, M. Muhsin, and P. Kirkpatrick, “Oxaliplatin. Market analysis,” Nature Reviews Drug Discovery, vol. 3, no. 1, pp. 11–12, 2004.
[30]
P. C. Kurniali, L. G. Luo, and A. B. Weitberg, “Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients,” Oncology, vol. 24, no. 3, pp. 289–292, 2010.
[31]
D. R. Pachman, D. L. Barton, J. C. Watson, and C. L. Loprinzi, “Chemotherapy-induced peripheral neuropathy: prevention and treatment,” Clinical Pharmacology and Therapeutics, vol. 90, no. 3, pp. 377–387, 2011.
[32]
B. Vincenzi, M. F. Anna, S. Gaia, et al., “Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV,” Supportive Care in Cancer, vol. 21, no. 5, pp. 1313–1319, 2013.
[33]
J. M. Schloss, C. Maree, A. Caroline, et al., “Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review,” Clinical Nutrition, 2013.
